Funding & Investment - Windtree Therapeutics (WINT), a Nasdaq-listed biotech company, secured up to $520 million in total funding [1] - The funding includes a $500 million equity line of credit (ELOC) agreement and an additional $20 million stock purchase deal [1] - Approximately 99% of the funds, equivalent to roughly $514.8 million, will be allocated to buy BNB (币安币) [1]

Core Viewpoint - Brazil Potash Corp has entered into a definitive agreement for an equity line of credit with Alumni Capital LP, which is expected to provide flexible funding for the Autazes Potash Project, crucial for global food security [1][3]. Funding Agreement - The equity line of credit allows Brazil Potash to sell up to $75 million worth of common shares over a 24-month period, with the company controlling the timing and amount of sales [3]. - The agreement is structured to provide Brazil Potash with a flexible financing tool as it progresses with early construction activities for the Autazes Project [2][3]. Project Overview - The Autazes Project aims to supply sustainable fertilizers to Brazil, which is heavily reliant on potash imports, having imported over 95% of its potash fertilizer in 2021 [6]. - Brazil Potash plans to produce up to 2.4 million tons of potash annually, potentially meeting approximately 20% of Brazil's current potash demand [6]. - The project is positioned to reduce Brazil's reliance on imports and mitigate around 1.4 million tons of greenhouse gas emissions per year [6].